Noncanonical NF-κB Signaling Upregulation in Inflammatory Bowel Disease Patients is Associated With Loss of Response to Anti-TNF Agents

Objectives: Targeting tumor necrosis factor (TNF) with biologic agents, such as infliximab and adalimumab, is a widely used and effective therapeutic strategy in inflammatory bowel disease (IBD). Unfortunately, a significant number of patients fail to respond or lose response over time to these agen...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Pharmacol
Main Authors: Nguyen, Vu Q., Eden, Kristin, Morrison, Holly A., Sammons, Megan B., Knight, Kristin K., Sorrentino, Siena, Brock, Rebecca M., Grider, Douglas J., Allen, Irving C., Sorrentino, Dario
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2021
Assuntos:
Pharmacology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8223059/
https://ncbi.nlm.nih.gov/pubmed/34177575
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2021.655887
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados